Literature DB >> 14750577

Adverse events of standardized regimens of corticosteroids for prophylaxis and treatment of nerve function impairment in leprosy: results from the 'TRIPOD' trials.

Jan H Richardus1, Stephen G Withington, Alison M Anderson, Richard P Croft, Peter G Nicholls, Wim H Van Brakel, W Cairns S Smith.   

Abstract

Reactions in leprosy causing nerve function impairment (NFI) are increasingly treated with standardized regimens of corticosteroids, often under field conditions. Safety concerns led to an assessment of adverse events of corticosteroids, based on data of three trials studying prevention of NFI (the TRIPOD study). A multicentre, randomized, double-blind placebo-controlled trial was conducted in leprosy control programmes in Nepal and Bangladesh. Treatment was with prednisolone according to fixed schedules for 16 weeks, starting in one trial with 20 mg/day (prophylactic regimen: total dosage 1.96 g) and in the other two trials with 40 mg/day (therapeutic regimen: total dosage 2.52 g). Minor adverse events were defined as moon face, fungal infections, acne, and gastric pain requiring antacid. Major adverse events were defined as psychosis, peptic ulcer, glaucoma, cataract, diabetes and hypertension. Also, the occurrence of infected plantar, palmar, and corneal ulceration was monitored, together with occurrence of TB. Considering all three trials together, minor adverse events were observed in 130/815 patients (16%). Of these, 51/414 (12%) were in the placebo group and 79/401 (20%) in the prednisolone group. The relative risk for minor adverse events in the prednisolone group was 1.6 (P = 0.004). Adverse events with a significantly increased risk were acne, fungal infections and gastric pain. Major adverse events were observed in 15/815 patients (2%); 7/414 (2%) in the placebo group and 8/401 (2%) in the prednisolone group. No major adverse events had a significantly increased risk in the prednisolone arm of the trials. No cases of TB were observed in 300 patients who could be followed-up for 24 months. Standardized regimens of corticosteroids for both prophylaxis and treatment of reactions and NFI in leprosy under field conditions in developing countries are safe when a standard pre-treatment examination is performed, treatment for minor conditions can be carried out by field staff, referral for specialized medical care is possible, and sufficient follow-up is done during and after treatment.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14750577

Source DB:  PubMed          Journal:  Lepr Rev        ISSN: 0305-7518            Impact factor:   0.537


  8 in total

Review 1.  Corticosteroid-sparing strategies in renal transplantation: are we still balancing rejection risk with improved tolerability?

Authors:  Oriol Bestard; Josep M Cruzado; Josep M Grinyó
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Steroid prophylaxis for prevention of nerve function impairment in leprosy: randomised placebo controlled trial (TRIPOD 1).

Authors:  W Cairns S Smith; Alison M Anderson; Stephen G Withington; Wim H van Brakel; Richard P Croft; Peter G Nicholls; Jan Hendrik Richardus
Journal:  BMJ       Date:  2004-05-24

3.  A phase two randomised controlled double blind trial of high dose intravenous methylprednisolone and oral prednisolone versus intravenous normal saline and oral prednisolone in individuals with leprosy type 1 reactions and/or nerve function impairment.

Authors:  Stephen L Walker; Peter G Nicholls; Sushmita Dhakal; Rachel A Hawksworth; Murdo Macdonald; Kishori Mahat; Shudan Ruchal; Sushma Hamal; Deanna A Hagge; Kapil D Neupane; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2011-04-12

4.  Coexistence of mycobacterial infections - Mycobacterium tuberculosis and Mycobacterium leprae - in Sri Lanka: a case series.

Authors:  B S D P Keragala; H M M T B Herath; G H D C Janapriya; S Vanitha; Thanushah Balendran; Thavarajah Janani; T S Keragala; C N Gunasekera
Journal:  J Med Case Rep       Date:  2020-07-16

5.  Two randomized controlled clinical trials to study the effectiveness of prednisolone treatment in preventing and restoring clinical nerve function loss in leprosy: the TENLEP study protocols.

Authors:  Inge Wagenaar; Wim Brandsma; Erik Post; Wim van Brakel; Diana Lockwood; Peter Nicholls; Paul Saunderson; Cairns Smith; Einar Wilder-Smith; Jan Hendrik Richardus
Journal:  BMC Neurol       Date:  2012-12-18       Impact factor: 2.474

6.  Diagnosis and treatment of leprosy reactions in integrated services--the patients' perspective in Nepal.

Authors:  Sonia F Raffe; Min Thapa; Saraswoti Khadge; Krishna Tamang; Deanna Hagge; Diana N J Lockwood
Journal:  PLoS Negl Trop Dis       Date:  2013-03-07

7.  The mortality associated with erythema nodosum leprosum in Ethiopia: a retrospective hospital-based study.

Authors:  Stephen L Walker; Eglantine Lebas; Shimelis N Doni; Diana N J Lockwood; Saba M Lambert
Journal:  PLoS Negl Trop Dis       Date:  2014-03-13

8.  Tuberculosis and Leprosy Coinfection: A Perspective on Diagnosis and Treatment.

Authors:  Lisa Mangum; Dustin Kilpatrick; Barbara Stryjewska; Rahul Sampath
Journal:  Open Forum Infect Dis       Date:  2018-06-05       Impact factor: 3.835

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.